Log In
Print
BCIQ
Print
Print this Print this
 

SMC-103

  Manage Alerts
Collapse Summary General Information
Company SMC Biotechnology Inc.
DescriptionGlycosaminoglycan (GAG) that enhances the pro-healing effects of endogenously produced bone morphogenetic protein 2 (BMP2)
Molecular Target Bone morphogenetic protein 2 (BMP2)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationBone repair
Indication DetailsEnhance bone repair; Promote long bone healing and spinal fusion as an alternative to bone graft and bone graft substitutes
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today